Eric Van Cutsem
埃里克·范·卡特塞姆
MD, PhD
Professor of Medicine; Head of Digestive Oncology, University Hospitals Leuven and KU Leuven医学教授，鲁汶大学医院及鲁汶大学消化道肿瘤科主任
👥Biography 个人简介
Eric Van Cutsem, MD, PhD is Professor of Medicine and Head of Digestive Oncology at University Hospitals Leuven and KU Leuven. He is one of the most prolific and internationally recognized clinical investigators in gastrointestinal oncology, with seminal contributions spanning gastric, esophageal, colorectal, and pancreatic cancers. In gastric cancer, Dr. Van Cutsem was the primary investigator of the RAINBOW trial, the phase III study demonstrating that ramucirumab plus paclitaxel significantly improved overall survival over paclitaxel alone in second-line advanced gastric and GEJ adenocarcinoma—a pivotal study that led to global regulatory approval of ramucirumab and established VEGFR2 inhibition as a second-line standard. He also contributed to the ToGA trial establishing trastuzumab in HER2-positive gastric cancer and has led multiple ESMO gastric cancer consensus processes. Dr. Van Cutsem has been a principal or co-investigator in over 300 clinical trials and has published more than 800 peer-reviewed articles with an h-index exceeding 130, making him among the most cited oncologists in Europe. He is a past president of ESMO and a member of multiple international guideline committees.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
RAINBOW — Ramucirumab plus Paclitaxel as Second-Line Standard in Gastric Cancer
Led RAINBOW, the phase III trial demonstrating that ramucirumab plus paclitaxel significantly improved overall survival (9.6 vs 7.4 months, HR 0.807) over placebo plus paclitaxel in second-line advanced gastric/GEJ adenocarcinoma, establishing this combination as a global second-line standard and leading to FDA and EMA approval of ramucirumab.
REGARD — Ramucirumab Monotherapy in Gastric Cancer
Co-led REGARD, the first phase III trial to demonstrate survival benefit of an anti-angiogenic agent as monotherapy in second-line advanced gastric/GEJ cancer, establishing ramucirumab monotherapy as an option for patients ineligible for paclitaxel-based combinations.
HER2 Targeting in Gastric and GEJ Cancer
Contributed to the global ToGA trial establishing trastuzumab plus chemotherapy as the first approved targeted therapy for HER2-positive advanced gastric and GEJ cancer, and subsequently to trials evaluating second-generation HER2-directed therapies in this indication.
ESMO Gastric Cancer Clinical Practice Guidelines
Led and co-authored multiple editions of the ESMO Clinical Practice Guidelines for gastric cancer, synthesizing trial evidence into European treatment standards and driving adoption of HER2 testing, PD-L1 assessment, and biomarker-stratified therapy selection across European oncology practice.
Representative Works 代表性著作
Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW)
The Lancet Oncology (2014)
Pivotal RAINBOW trial establishing ramucirumab plus paclitaxel as second-line standard in advanced gastric/GEJ adenocarcinoma with significant overall survival benefit.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD)
The Lancet (2014)
Phase III REGARD trial showing that ramucirumab monotherapy improved overall survival over placebo in second-line advanced gastric/GEJ cancer.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA)
The Lancet (2010)
ToGA trial establishing trastuzumab as the first targeted therapy approved for HER2-positive advanced gastric and GEJ adenocarcinoma.
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Annals of Oncology (2016)
Landmark ESMO Clinical Practice Guidelines for gastric cancer providing evidence-based European treatment standards incorporating targeted therapy, perioperative regimens, and palliative care.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-04-06 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 埃里克·范·卡特塞姆 的研究动态
Follow Eric Van Cutsem's research updates
留下邮箱，当我们发布与 Eric Van Cutsem（University Hospitals Leuven / KU Leuven）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment